Impact BioMedical, Inc.(IBO)
$4.30-0.32 (-6.93%)
IBO
Impact BioMedical, Inc. financials statements
$4.30
At close:-0.32 (-6.93%)
Impact BioMedical, Inc. (IBO) Ratios
107 Followers
Impact BioMedical, Inc. Ratios
IBO's free cash flow for Q2 2026 was C$470.00K. For the 2026 fiscal year, IBO's free cash flow was increased by C$0.00 and operating cash flow was C$470.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.35 | 0.25 | 0.03 | 0.01 | 0.02 |
| Quick Ratio | 0.30 | 0.25 | 0.03 | 0.01 | 0.02 |
| Cash Ratio | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 |
| Solvency Ratio | -5.78 | -0.09 | -0.26 | -0.43 | -0.01 |
| Operating Cash Flow Ratio | -1.63 | -0.58 | -0.22 | -0.21 | -0.16 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -0.63 | -0.24 | -0.22 | -0.16 |
| Net Current Asset Value | C$ -1.44M | C$ -10.61M | C$ -16.04K | C$ -13.71K | C$ -16.21K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.44 | 0.27 | 0.21 | 0.22 |
| Debt-to-Equity Ratio | 0.00 | 2.08 | 0.48 | 0.34 | 0.34 |
| Debt-to-Capital Ratio | 0.00 | 0.68 | 0.32 | 0.25 | 0.25 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.38 | 4.76 | 1.77 | 1.57 | 1.54 |
| Debt Service Coverage Ratio | -12.52 | -0.12 | -0.33 | -0.29 | -0.28 |
| Interest Coverage Ratio | -5.38 | 3.27 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.32 | 0.22 | 0.20 | 0.14 | 0.18 |
| Net Debt to EBITDA | 0.00 | -6.43 | -3.00 | -4.36 | -6.02 |
| Profitability Margins | |||||
| Gross Profit Margin | -1225.00% | 100.00% | 0.00% | 100.00% | 0.00% |
| EBIT Margin | -42678.13% | -80.76% | 0.00% | -6808.00% | 0.00% |
| EBITDA Margin | -39100.00% | -66.03% | 0.00% | -4581.33% | 0.00% |
| Operating Profit Margin | -13343.75% | 23.67% | 0.00% | -6808.00% | 0.00% |
| Pretax Profit Margin | -45156.25% | -88.01% | 0.00% | -15752.00% | 0.00% |
| Net Profit Margin | -36993.75% | -88.01% | 0.00% | -14102.00% | 0.00% |
| Continuous Operations Profit Margin | -37093.75% | -88.01% | 0.00% | -14510.00% | 0.00% |
| Net Income Per EBT | 81.92% | 100.00% | 98.39% | 89.53% | 40.18% |
| EBT Per EBIT | 338.41% | -371.89% | 109.41% | 231.37% | 101.82% |
| Return on Assets (ROA) | -68.01% | -7.03% | -9.71% | -15.16% | -2.31% |
| Return on Equity (ROE) | -93.89% | -33.47% | -17.19% | -23.86% | -3.56% |
| Return on Capital Employed (ROCE) | -26.29% | 3.65% | -12.79% | -9.48% | -7.28% |
| Return on Invested Capital (ROIC) | -21.59% | 1.98% | -9.24% | -8.00% | -8.09% |
| Return on Tangible Assets | -2880.29% | -57.44% | -700.48% | -514.67% | -12.79% |
| Earnings Yield | -74.33% | -2.35% | -0.02% | -0.03% | -0.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.16 | 8.80 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.22 | 1.57 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 6.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 95.28 | 0.00 | 0.18 | 0.00 |
| Asset Turnover | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | -0.01 | -0.16 | 0.00 | -0.00 | 0.00 |
| Cash Conversion Cycle | 2070.99 | -191.11 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 2315.47 | 41.46 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 54.23 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 298.71 | 232.57 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 2369.70 | 41.46 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.76 | -0.13 | -0.05 | -0.03 | -0.03 |
| Free Cash Flow Per Share | -0.76 | -0.13 | -0.05 | -0.04 | -0.03 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -158.39 | -8.12 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -158.39 | -8.12 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | -0.63 | -0.24 | -0.22 | -0.16 |
| Operating Cash Flow to Sales Ratio | -59.06 | -3.48 | 0.00 | -44.84 | 0.00 |
| Free Cash Flow Yield | -11.87% | -9.31% | -0.01% | -0.01% | -0.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.33 | -210.14 | -5398.14 | -3884.23 | -21019.25 |
| Price-to-Sales (P/S) Ratio | 497.66 | 37.38 | 0.00 | 547753.92 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.26 | 14.22 | 928.01 | 926.61 | 748.12 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.43 | -10.74 | -8158.36 | -10876.77 | -13511.64 |
| Price-to-Operating Cash Flow Ratio | -8.43 | -10.74 | -8209.87 | -12215.74 | -13511.64 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 2.33 | 192.79 | -8.82 | -178.66 |
| Enterprise Value Multiple | -1.27 | -63.04 | -5822.58 | -11960.57 | -13226.34 |
| Enterprise Value | 15.92M | 67.42M | 23.42M | 27.40M | 27.40M |
| EV to EBITDA | -1.27 | -63.04 | -5822.58 | -11960.57 | -13226.34 |
| EV to Sales | 497.57 | 41.62 | 0.00 | 547953.70 | 0.00 |
| EV to Free Cash Flow | -8.42 | -11.96 | -8162.57 | -10880.73 | -13517.79 |
| EV to Operating Cash Flow | -8.42 | -11.96 | -8214.11 | -12220.20 | -13517.79 |
| Tangible Book Value Per Share | -0.58 | -0.25 | -0.26 | -0.18 | -0.09 |
| Shareholders’ Equity Per Share | 5.04 | 0.10 | 0.42 | 0.42 | 0.52 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.18 | -0.02 | 0.00 | -0.08 | -0.43 |
| Revenue Per Share | 0.01 | 0.04 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -4.74 | -0.03 | -0.07 | -0.10 | -0.02 |
| Tax Burden | 0.82 | 1.00 | 0.98 | 0.90 | 0.40 |
| Interest Burden | 1.06 | 1.09 | 1.09 | 2.31 | 1.02 |
| Research & Development to Revenue | 10.63 | 0.04 | 0.00 | 24.52 | 0.00 |
| SG&A to Revenue | 61.75 | 0.44 | 0.00 | 15.80 | 0.00 |
| Stock-Based Compensation to Revenue | 0.41 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.16 | 0.16 | 0.66 | 0.32 | 1.56 |
Currency in CAD
